Last reviewed 2026-05-29 · How we verify

Triaziquon (TRIAZIQUONE)

Phase 2 active Small molecule ✓ Verified May 2026

Triaziquon (generic name: TRIAZIQUONE) is a triaziquone drug. It is currently in Phase 2 development.

Triaziquone works by interacting with a specific cellular target to produce its therapeutic effects.

Triaziquon is a small molecule. It is also known by various synonyms, including BAYER 3231, RIKER 601, and NSC-29215.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TRIAZIQUONE
Drug class	triaziquone
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine triaziquone as a key that fits into a lock on a cell. When it binds to this lock, it triggers a series of events that ultimately lead to the desired therapeutic outcome. However, the exact details of how triaziquone interacts with its target and the downstream effects are not yet fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Triaziquon CI brief — competitive landscape report
Triaziquon updates RSS · CI watch RSS

Frequently asked questions about Triaziquon

What is Triaziquon?

Triaziquon (TRIAZIQUONE) is a triaziquone drug.

How does Triaziquon work?

Triaziquone works by interacting with a specific cellular target to produce its therapeutic effects.

What is the generic name of Triaziquon?

TRIAZIQUONE is the generic (nonproprietary) name of Triaziquon.

What drug class is Triaziquon in?

Triaziquon belongs to the triaziquone class. See all triaziquone drugs at /class/triaziquone.

What development phase is Triaziquon in?

Triaziquon is in Phase 2.

Drug class: All triaziquone drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing